Edgar Filing: ATOSSA GENETICS INC - Form 4

	ENETICS INC										
Form 4	016										
January 21, 2016								OMB A	OMB APPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction See Instruction Form 5 See Instruction See Instruction						e Act of 1934, f 1935 or Sectio	Expires: Estimated a burden hou response	rs per			
See Instru 1(b).	ction	50(11)	of the my	estinent v	company	1101	0117-	10			
(Print or Type R	esponses)										
Chen Shu-Chih Symbol			Symbol	er Name and Ticker or Trading SA GENETICS INC [ATOS]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First)	(Middle)	3. Date of	Earliest Tra	ansaction			(Click	.k all applicable	2)	
(Month/D C/O ATOSSA GENETICS, 01/19/20 INC., 2300 EASTLAKE AVE. EAST, SUITE 200			-				X Director Officer (give below)	Officer (give title Other (specify			
Filed(Mont			ndment, Date Original th/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
SEATTLE, V	WA 98102							Person	viore than One Ke	porting	
(City)	(State)	(Zip)	Table	e I - Non-De	erivative S	ecurit	ies Acq	uired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction E (Month/Day/Ye	ar) Executio any		Code	on(A) or Dis (D)	posed	l of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	01/19/2016			Code V P <u>(1)</u>	Amount 50,000	(D) A	Price \$ 0.2	4,318,315	I	See Footnote (2)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: ATOSSA GENETICS INC - Form 4

Reporting Owners

Relationships					
Director	10% Owner	Officer	Other		
Х	Х				
	21100101	Director 10% Owner	Director 10% Owner Officer		

/s/ Shu-Chih	01/21/2016			
Chen	01/21/2010			
<u>**Signature of</u>	Date			

Signature of **Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents 50,000 shares purchased in an at-market transaction directly from Atossa Genetics, Inc.

Consists of 4,318,315 shares of common stock owned by Ensisheim Partners, LLC ("Ensisheim"). Shu-Chih Chen, Ph.D. and Steven C. Quay, M.D., Ph.D., share voting and investment power over the securities held by Ensisheim. Ensisheim is solely (2)owned and controlled by Drs. Chen and Quay, and, as a result, Drs. Chen and Quay are deemed to be beneficial owners of the shares held by this entity.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.